An Early Phase 1 interventional study of Tacrolimus and Calcipotriol in Vitiligo - Macular Depigmentation and Tacrolimus, sponsored by Dr ayesha wahid. Enrolling by invitation at 1 site in Pakistan. Open to participants aged 15 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-24.
Sponsored by Dr ayesha wahid · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tacrolimus in Vitiligo — 2 open to participants now, 2 under way, none of them phase 3. Tacrolimus · Vitiligo.
Among the 11 studies testing tacrolimus in Vitiligo, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 1, and was the 9th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →2 of the 11 studies testing tacrolimus in Vitiligo are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 4–12
By country, each count listing its studies:
Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 15 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 3 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 51 across the 10 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dr ayesha wahid as lead sponsor.
Dr ayesha wahid has 1 study filed under Vitiligo — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing tacrolimus in Vitiligo, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed
Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and VIisual analogie scale
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months
Exclusion Criteria:
Pregnant or lactating female patients.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient of Limited vitiligo less than 20% BSA will be treated with topical tacrolimus and narrowband UVB
Drug: Tacrolimus
Calcipotriol is a vitamin D analogue that will act as immunomodulator
Drug: Calcipotriol
Tacrolimus is calcineurin inhibitor that will act as immunomodulator
Calcipotriol is a vitamin D analogue that will act as immunomodulator
VASI improvement upto 50%
Improvement in VASI score upto 50%
Time frame: 3 months
Started May 2025 (actual). Primary completion is estimated for Jun 2025, 1 month after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tacrolimus · Calcipotriene